Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Cerebrolysin | PT-141 (Bremelanotide) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization. | Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity. |
| Timing | Morning administration preferred for cognitive effects. IV infusion over 15-20 minutes. | 45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response. |
| Cycle Duration | 10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance. | As-needed basis. Not intended for daily use. |
| Evidence Level | moderate_human | strong_human |
Cerebrolysin is a porcine brain-derived peptide preparation containing a standardized mixture of low-molecular-weight neuropeptides (<10 kDa) and free amino acids obtained through enzymatic proteolysis. It exerts multimodal neurotrophic effects by simultaneously upregulating VEGF, BDNF, IGF-1, and NGF while downregulating TNF-alpha. Cerebrolysin increases furin protease concentration, which promotes pro-NGF to mature NGF conversion. It activates TrkB receptor signaling (BDNF/TrkB/CREB pathway), inhibits neuronal apoptosis, reduces microglial activation, and promotes neurogenesis.
Research indicates 10-30 mL daily via intravenous infusion for neurological indications. 5-10 mL for cognitive optimization.
Morning administration preferred for cognitive effects. IV infusion over 15-20 minutes.
10-20 day intensive cycles repeated every 3-6 months. Some protocols use ongoing 3x weekly maintenance.
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin analog that acts as an agonist at MC3R and MC4R melanocortin receptors, with higher affinity for MC4R. It enhances sexual desire by activating presynaptic MC4Rs on neurons in the medial preoptic area (mPOA) of the hypothalamus, increasing dopamine release — an excitatory neurotransmitter for sexual desire. Unlike PDE5 inhibitors, PT-141 works centrally through the CNS rather than peripherally on blood flow, addressing desire rather than just erectile mechanics.
Research indicates 1.75 mg administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity.
45-60 minutes before anticipated sexual activity. Effects last 6-72 hours depending on individual response.
As-needed basis. Not intended for daily use.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →